Answers are grounded in this paper and cite their sources.
Aim: The aim of this study was to develop a lung-targeted, mouse model of cigarette smoke-induced inflammation that can be used to study the pathophysiological changes that occur in the lungs of human smokers and patients with chronic obstructive pulmonary disease (COPD).Materials & methods: Cigarette smoke extract (CSE) was prepared freshly daily.Intranasal administration into female mice was performed once daily for up to 3 weeks.Results: CSE significantly increased airway macrophages after 3 and 4 days of dosing, and then declined over the subsequent 2 weeks.However, airway neutrophils were elevated after a single dose of CSE, and at all subsequent time points.Muc5AC was significantly increased in the Bronchoalveolar lavage (BAL) of CSE-treated animals compared to control mice (P<0.05),but TNF-α concentrations decreased in a dose-dependent manner.In animals challenged with CSE for 4 consecutive days, a PDE4 inhibitor (Roflumilast; 10 mg/kg BID) significantly inhibited both macrophages (P<0.01) and neutrophils (P<0.001), a steroid (prednisolone; 10 mg/kg BID) had no effect on either macrophages or neutrophils and an oral p38 inhibitor (PHA-818637; 10 mg/kg BID) inhibited macrophages (P<0.05),but not neutrophils.CSE inhibited lipopolysaccharide-induced airway neutrophilia.Conclusion: This model reflects many aspects of human COPD including pulmonary leucocytes, mucin, TNF-α and response to clinical therapeutic agents and may be useful in assessing the efficacy of potential therapies.
No takes yet. Share an insight, caveat, or question.
Lamb et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: